In Brief:
Clostridium difficile infection (CDI) incidence has doubled from 2001 to 2010. Despite appropriate therapy, the likelihood of first recurrence is 10–20%, which subsequently increases to 40–65% after the initial recurrence. Bexlotoxumab is a new monoclonal antibody that provides passive immunity against the virulent toxin B produced by C. difficile during an infection. Bezlotoxumab showed a 10% reduction in recurrent CDI infections compared to placebo when used with standard of care antibiotics.
